[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586428":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":91,"collaborators":25,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":25,"eligibilityCriteria":99,"healthyVolunteers":95,"sex":100,"minAge":101,"maxAge":25,"enrollmentInfo":102,"targetDuration":25,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"VIVUS LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"VI-0609","EXPERIMENTAL","VI-0609 (Carmustine with Propylene Glycol)",[13],"Drug: VI-0609",{"label":15,"type":16,"description":17,"interventionNames":18},"BiCNU","ACTIVE_COMPARATOR","BiCNU (Carmustine with Ethanol)",[19],"Drug: BiCNU",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Carmustine with Propylene Glycol",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Carmustine with Ethanol",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"VIVUS Clinical","CONTACT","+1-888-998-4887","clinical@vivus.com",[36,55,67,79],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"City of Hope Phoenix","RECRUITING","Goodyear","Arizona","85338","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-112.35821,33.43532,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":53,"phoneExt":25,"email":54},"Anna Keryan","626-218-1124","akeryan@coh.org",{"facility":56,"status":38,"city":57,"state":58,"zip":59,"country":42,"countryCode":43,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"City of Hope National Medical Center","Duarte","California","91010",{"type":45,"coordinates":61},[62,63],-117.97729,34.13945,{"lat":63,"lon":62},[66],{"name":52,"role":32,"phone":53,"phoneExt":25,"email":54},{"facility":68,"status":38,"city":69,"state":70,"zip":71,"country":42,"countryCode":43,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"City of Hope Atlanta","Newnan","Georgia","30265",{"type":45,"coordinates":73},[74,75],-84.79966,33.38067,{"lat":75,"lon":74},[78],{"name":52,"role":32,"phone":53,"phoneExt":25,"email":54},{"facility":80,"status":38,"city":81,"state":82,"zip":83,"country":42,"countryCode":43,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"City of Hope Chicago","Zion","Illinois","60099",{"type":45,"coordinates":85},[86,87],-87.83285,42.44613,{"lat":87,"lon":86},[90],{"name":52,"role":32,"phone":53,"phoneExt":25,"email":54},{"type":92,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100586428","phase-2-a-study-of-carmustine-with-and-without-ethanol-in-subjects-with-lymphoma-100586428",false,"NCT06915246","A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma","A Randomized Phase 2 Study of Carmustine Formulated With and Without Ethanol as Part of BEAM Chemotherapy Conditioning for Subjects With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (AHCT)","Inclusion Criteria:\n\n* Male and female adults ≥ 18 years of age with a life expectancy ≥ 6 months;\n* Karnofsky performance status ≥ 70%;\n* Histologically confirmed Hodgkin lymphoma or Non-Hodgkin lymphoma;\n* Candidate for AHCT consolidation therapy as assessed by their treating physician;\n* Achieved a complete or partial response;\n* Completed collection of at least 2.0 x 10\\^6 CD34 cells\u002Fkg of autologous hematopoietic progenitor cells (HPCs) by apheresis;\n* Recovery from non-hematologic toxicities of salvage cytoreductive chemotherapy to ≤ grade 2;\n* Clinical laboratory and organ function criteria meeting study ranges\u002Flimits LVEF ≥ 50%; FEV1 \\> 65% of predicted measurement, DLCO ≥ 50% of predicted;\n* Seronegative for HIV Ag\u002FAb combo, HCV, active HBV, and syphilis\n\nExclusion Criteria:\n\n* Prior high-dose chemotherapy with autologous stem cell transplant, or prior allogeneic transplantation;\n* Significant prior external beam dose-limiting radiation to a critical organ based on review of the prior radiation treatment records;\n* Use of any other investigational medication or device, or concurrent biological, chemotherapy, or radiation therapy;\n* Myelodysplasia or any active malignancy other than HL or NHL, or \\\u003C 5 years remission from any other prior malignancy;\n* Any cytogenetic abnormality in the bone marrow that is known to be associated with or predictive of myelodysplasia;\n* Persistent marrow involvement (\\>10%) with HL or NHL after salvage cytoreductive therapy and before stem cell mobilization;\n* Not having sufficient bone marrow harvest to reach adequate cell dose for transplant;\n* Active hepatitis B or C viral infection or HBsAg positive;\n* Positive HIV antibody;","ALL","18 Years",{"count":103,"type":104},49,"ESTIMATED","INTERVENTIONAL",[107],"PHASE2","A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.",[110,111,112],"Lymphoma","Non-Hodgkin Lymphoma","Hodgkin Lymphoma",[110,114,15,115],"AHCT","Carmustine","2026-03-25",{"date":118,"type":119},"2026-03-27","ACTUAL",{"date":121,"type":119},"2025-03-12",{"date":123,"type":104},"2027-04-30",{"name":5,"class":6},4]